Your browser is no longer supported. Please, upgrade your browser.
Settings
NVAX Novavax, Inc. daily Stock Chart
NVAX [NASD]
Novavax, Inc.
Index- P/E- EPS (ttm)-2.76 Insider Own0.70% Shs Outstand58.62M Perf Week13.53%
Market Cap6.46B Forward P/E4.98 EPS next Y21.75 Insider Trans-31.47% Shs Float55.24M Perf Month-26.32%
Income-93.30M PEG- EPS next Q1.83 Inst Own53.00% Short Float15.35% Perf Quarter67.35%
Sales50.20M P/S128.69 EPS this Y44.90% Inst Trans152.64% Short Ratio1.06 Perf Half Y946.96%
Book/sh3.15 P/B34.40 EPS next Y139.45% ROA-23.30% Target Price- Perf Year1505.33%
Cash/sh8.43 P/C12.86 EPS next 5Y0.00% ROE173.30% 52W Range3.54 - 189.40 Perf YTD2622.61%
Dividend- P/FCF201.89 EPS past 5Y5.60% ROI- 52W High-42.79% Beta1.45
Dividend %- Quick Ratio3.00 Sales past 5Y-9.50% Gross Margin- 52W Low2961.02% ATR13.00
Employees165 Current Ratio3.00 Sales Q/Q944.10% Oper. Margin- RSI (14)46.07 Volatility11.57% 11.21%
OptionableYes Debt/Eq1.74 EPS Q/Q82.30% Profit Margin- Rel Volume0.73 Prev Close115.51
ShortableYes LT Debt/Eq1.74 EarningsAug 10 AMC Payout- Avg Volume7.98M Price108.36
Recom2.70 SMA20-0.28% SMA50-15.05% SMA200120.28% Volume5,802,359 Change-6.19%
Aug-06-20Reiterated H.C. Wainwright Buy $132 → $290
Aug-05-20Upgrade JP Morgan Neutral → Overweight $275
Aug-05-20Downgrade Ladenburg Thalmann Neutral → Sell $105
Jul-16-20Reiterated H.C. Wainwright Buy $101 → $132
Jul-08-20Downgrade Ladenburg Thalmann Buy → Neutral $50 → $105
Jun-29-20Reiterated H.C. Wainwright Buy $50 → $101
Jun-29-20Reiterated B. Riley FBR Buy $74 → $106
Jun-05-20Upgrade JP Morgan Underweight → Neutral $46
May-28-20Reiterated B. Riley FBR Buy $53 → $61
May-12-20Reiterated H.C. Wainwright Buy $33 → $50
Apr-30-20Reiterated H.C. Wainwright Buy $24 → $33
Nov-27-19Resumed B. Riley FBR Buy $12
Aug-14-19Reiterated H.C. Wainwright Buy $10 → $17
Feb-28-19Downgrade Piper Jaffray Overweight → Underweight $4.50 → $0.25
Dec-18-18Initiated Ladenburg Thalmann Buy $3
Dec-11-18Initiated Oppenheimer Outperform $4
Nov-26-18Upgrade Piper Jaffray Neutral → Overweight
Sep-21-18Upgrade JP Morgan Underweight → Overweight
Mar-29-18Upgrade Seaport Global Securities Neutral → Buy $5
Mar-19-18Downgrade JP Morgan Neutral → Underweight
Sep-19-20 08:55AM  
Sep-18-20 04:44PM  
03:12PM  
11:56AM  
09:26AM  
Sep-17-20 05:02PM  
04:54PM  
07:26AM  
Sep-16-20 02:04PM  
12:50PM  
Sep-15-20 06:06PM  
04:27PM  
03:49PM  
03:41PM  
02:06PM  
11:58AM  
11:10AM  
07:55AM  
07:25AM  
07:00AM  
06:04AM  
Sep-14-20 04:27PM  
11:58AM  
Sep-13-20 05:10AM  
Sep-11-20 11:51AM  
Sep-10-20 04:19PM  
07:00AM  
06:50AM  
06:12AM  
Sep-09-20 06:20PM  
04:13PM  
01:57PM  
11:30AM  
09:17AM  
06:45AM  
Sep-08-20 04:39PM  
04:29PM  
04:15PM  
03:14PM  
01:52PM  
11:39AM  
08:54AM  
06:30AM  
Sep-06-20 06:11AM  
Sep-05-20 07:46AM  
Sep-04-20 05:04PM  
01:51PM  
12:01PM  
11:20AM  
Sep-03-20 07:01PM  
04:15PM  
04:12PM  
03:31PM  
02:50PM  
01:59PM  
01:03PM  
12:47PM  
10:44AM  
09:57AM  
09:35AM  
09:19AM  
08:24AM  
07:55AM  
07:50AM  
Sep-02-20 06:31PM  
05:14PM  
11:48AM  
06:37AM  
02:09AM  
Sep-01-20 05:41PM  
11:34AM  
11:21AM  
Aug-31-20 04:10PM  
12:45PM  
12:28PM  
10:28AM  
10:00AM  
08:55AM  
08:21AM  
07:44AM  
Aug-30-20 12:41PM  
09:22AM  
Aug-29-20 08:08AM  
07:13AM  
Aug-28-20 01:51PM  
12:03PM  
08:31AM  
08:16AM  
07:59AM  
06:08AM  
Aug-27-20 06:09PM  
04:16PM  
03:44PM  
03:26PM  
01:30PM  
11:18AM  
07:30AM  
03:42AM  
Aug-26-20 11:25AM  
Aug-25-20 03:07PM  
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EVANS GARY CDirectorAug 18Option Exercise31.0210,500325,700332,479Aug 20 06:09 PM
Glenn Gregory MPresident, R&DAug 18Option Exercise33.5655,9211,876,52557,760Aug 20 06:14 PM
Herrmann John A IIIEVP, Chief Legal OfficerAug 18Option Exercise53.8246,2422,488,61346,517Aug 20 06:20 PM
MCMANUS MICHAEL A JRDirectorAug 18Option Exercise27.608,000220,80017,951Aug 20 06:22 PM
Trizzino JohnEVP, CBO and CFOAug 18Option Exercise50.9542,7882,179,98647,875Aug 20 06:25 PM
MCMANUS MICHAEL A JRDirectorAug 18Sale146.008,0001,168,0009,951Aug 20 06:22 PM
Herrmann John A IIIEVP, Chief Legal OfficerAug 18Sale144.3346,2426,673,982275Aug 20 06:20 PM
Trizzino JohnEVP, CBO and CFOAug 18Sale148.7842,7886,366,1825,087Aug 20 06:25 PM
Glenn Gregory MPresident, R&DAug 18Sale145.2055,9218,119,8601,839Aug 20 06:14 PM
EVANS GARY CDirectorAug 18Sale150.4410,5001,579,620321,979Aug 20 06:09 PM
Glenn Gregory MPresident, R&DJun 18Option Exercise42.2016,749706,80818,588Jun 22 05:29 PM
Glenn Gregory MPresident, R&DJun 18Sale59.5316,749997,1031,839Jun 22 05:29 PM
YOUNG JAMES FDirectorJun 03Buy48.831,50073,2451,500Jun 05 05:04 PM
Herrmann John A IIISVP, General CounselMay 18Option Exercise26.1912,961339,4487,774May 20 04:35 PM
Herrmann John A IIISVP, General CounselMay 18Sale49.4412,961640,792275May 20 04:35 PM
Glenn Gregory MPresident, R&DJan 31Buy3.861,2504,8251,373Feb 04 05:11 PM
MCMANUS MICHAEL A JRDirectorNov 18Sale3.823,92915,0159,951Nov 20 04:17 PM